Volastra Therapeutics has filed a notice of an exempt offering of securities to raise $60,174,997.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Volastra Therapeutics is raising $60,174,997.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Charles Hugh-Jones played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Volastra Therapeutics
Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancers most targetable vulnerability. Founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., Volastra is rapidly developing and implementing new methods to exploit this vulnerability. Leveraging its proprietary CINtech platform, the company is advancing a novel synthetic lethal and immune activating pipeline.
To learn more about Volastra Therapeutics, visit http://www.volastratx.com/
Contact:
Charles Hugh-Jones, Chief Executive Officer
646-344-1248
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.